|
시장보고서
상품코드
2132247
말라리아 치료제 시장 규모, 점유율, 동향 분석 보고서 : 약물 계열별, 적응증별, 투여 경로별, 유통 채널별, 지역별 및 부문별 예측(2026-2033년)Malaria Therapeutics Market Size, Share & Trends Analysis Report By Drug Class, By Therapeutic Indication, By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2026 - 2033 |
||||||
말라리아 치료제 시장 요약
세계의 말라리아 치료제 시장 규모는 2025년에 31억 달러로 평가되며, 2026년 32억 달러에서 2033년까지 50억 달러로 확대될 것으로 예상되며, 2026년부터 2033년까지 연평균 성장률(CAGR)은 6.5%에 달할 것으로 예측됩니다.
중동 및 아프리카이 시장을 주도하며, 2025년에는 매출 점유율의 47.1%를 차지했습니다. 말라리아 치료제 산업의 성장은 유행 지역, 특히 사하라 이남 아프리카 및 아시아태평양 일부에서 말라리아가 지속적으로 부담으로 작용함에 따라 견인되고 있습니다. 이러한 지역에서는 감염이 지속됨에 따라 효과적인 치료법에 대한 안정적인 수요가 창출되고 있습니다.
말라리아 치료제 시장의 성장은 풍토병 지역, 특히 사하라 이남 아프리카 및 아시아태평양의 일부에서 지속되는 말라리아의 부담에 의해 주도되고 있으며, 이러한 지역에서는 감염이 지속됨에 따라 효과적인 치료법에 대한 안정적인 수요가 발생하고 있습니다.
시장의 성장은 정부 주도의 말라리아 대책 프로그램, 국제 보건 기구의 자금 지원, 그리고 공중보건 이니셔티브를 통한 아르테미시닌 기반 복합요법(ACT)의 접근성 향상에 힘입어 뒷받침되고 있습니다. 약물 내성을 가진 열대열 말라리아 원충(Plasmodium falciparum) 균주에 대한 감시 체계가 강화됨에 따라, 제약 회사와 연구 기관은 새로운 항말라리아 치료제 및 병용요법의 개발을 추진하도록 장려받고 있습니다. 또한, 진단 접근성 개선과 조기 발견을 통해 적시 치료가 강화되어 질병 관리 향상에 기여하고 있습니다. 예를 들어, 2025년 7월, 노바티스는 ‘Medicines for Malaria Venture(MMV)’와 공동으로 신생아 및 영유아를 위해 특별히 개발된 최초의 말라리아 치료제인 ‘코아템 베이비(알테메테르·루메판트린)’에 대해 스위스 의약품청(Swissmedic)의 승인을 획득했습니다. 이를 통해 말라리아 유행 지역에서 오랫동안 지속되어 온 치료 공백이 해소되었으며, 연령에 맞는 항말라리아 치료에 대한 보다 광범위한 접근이 촉진되었습니다.
자주 묻는 질문
목차
제1장 조사 방법과 범위
제2장 주요 요약
제3장 말라리아 치료제 시장 : 변수, 동향, 범위
제4장 말라리아 치료제 시장 : 약물 계열별 비즈니스 분석
제5장 말라리아 치료제 시장 : 치료 적응증별 사업 분석
제6장 말라리아 치료제 시장 : 투여 경로별 비즈니스 분석
제7장 말라리아 치료제 시장 : 유통 채널별 비즈니스 분석
제8장 말라리아 치료제 시장 : 지역별 추정·동향 분석
제9장 경쟁 구도
KSMMalaria Therapeutics Market Summary
The global malaria therapeutics market size was valued at USD 3.1 billion in 2025 and is projected to grow from USD 3.2 billion in 2026 to USD 5.0 billion by 2033, at a CAGR of 6.5% from 2026 to 2033. The Middle East & Africa dominated the market, accounting for the largest revenue share of 47.1% in 2025. The malaria therapeutics industry growth is driven by the continued burden of malaria in endemic regions, particularly across sub-Saharan Africa and parts of the Asia Pacific, where sustained transmission creates consistent demand for effective treatment options.
The malaria therapeutics industry growth is driven by the continued burden of malaria in endemic regions, particularly across sub-Saharan Africa and parts of the Asia Pacific, where sustained transmission creates consistent demand for effective treatment options.
Growth in the market is supported by government-led malaria control programs, funding from international health organizations, and the increasing availability of artemisinin-based combination therapies (ACTs) through public health initiatives. Rising surveillance for drug-resistant Plasmodium falciparum strains has encouraged pharmaceutical companies and research organizations to advance the development of novel antimalarial therapies and combination regimens. In addition, improvements in diagnostic access and early case detection have strengthened timely treatment, contributing to better disease management. For instance, in July 2025, Novartis, in collaboration with Medicines for Malaria Venture (MMV), received Swissmedic approval for Coartem Baby (artemether-lumefantrine), the first malaria treatment specifically developed for newborns and young infants, addressing a long-standing treatment gap in malaria-endemic regions and supporting broader access to age-appropriate antimalarial therapies.
Global Malaria Therapeutics Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global malaria therapeutics market report based on drug class, therapeutic indication, route of administration, distribution channel, and region:
- Drug Class Outlook (Revenue, USD Billion, 2021 - 2033)
- Artemisinin-based Combination Therapies (ACTs)
- Non-Artemisinin Antimalarial Drugs
- 8-Aminoquinolines
- Therapeutic Indication Outlook (Revenue, USD Billion, 2021 - 2033)
- Uncomplicated Malaria
- Severe Malaria
- Relapse Prevention (Radical Cure)
- Malaria Chemoprophylaxis
- Route of Administration Outlook (Revenue, USD Billion, 2021 - 2033)
- Oral
- Parenteral
- Distribution Channel Outlook (Revenue, USD Billion, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Government & Institutional Procurement
- Regional Outlook (Revenue, USD Billion, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Drug Class
- 1.2.2. Therapeutic Indication
- 1.2.3. Route of Administration
- 1.2.4. Distribution Channel
- 1.3. Estimates and Forecast Timeline
- 1.4. Research Methodology
- 1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR's Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
- 1.6. Information Analysis
- 1.6.1. Data Analysis Models
- 1.7. Market Formulation & Data Visualization
- 1.8. Model Details
- 1.8.1. Commodity Flow Analysis
- 1.9. List of Secondary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. Malaria Therapeutics Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
- 3.3. Business Environment Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
- 3.3.1.1. Supplier Power
- 3.3.1.2. Buyer Power
- 3.3.1.3. Substitution Threat
- 3.3.1.4. Threat of New Entrants
- 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis
- 3.3.3. Pipeline Analysis
- 3.3.4. Patent Expiry Analysis
- 3.3.5. Pricing Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
Chapter 4. Malaria Therapeutics Market: Drug Class Business Analysis
- 4.1. Drug Class Market Share, 2025 & 2033
- 4.2. Drug Class Segment Dashboard
- 4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2021 to 2033 (USD Billion)
- 4.4. Artemisinin-based Combination Therapies (ACTs)
- 4.4.1. Artemisinin-based Combination Therapies (ACTs) Market, 2021 - 2033 (USD Billion)
- 4.5. Non-Artemisinin Antimalarial Drugs
- 4.5.1. Non-Artemisinin Antimalarial Drugs Market, 2021 - 2033 (USD Billion)
- 4.6. 8-Aminoquinolines
- 4.6.1. 8-Aminoquinolines Market, 2021 - 2033 (USD Billion)
Chapter 5. Malaria Therapeutics Market: Therapeutic Indication Business Analysis
- 5.1. Therapeutic Indication Market Share, 2025 & 2033
- 5.2. Therapeutic Indication Segment Dashboard
- 5.3. Market Size & Forecasts and Trend Analysis, by Therapeutic Indication, 2021 to 2033 (USD Billion)
- 5.4. Uncomplicated Malaria
- 5.4.1. Uncomplicated Malaria Market, 2021 - 2033 (USD Billion)
- 5.5. Severe Malaria
- 5.5.1. Severe Malaria Market, 2021 - 2033 (USD Billion)
- 5.6. Relapse Prevention (Radical Cure)
- 5.6.1. Relapse Prevention (Radical Cure) Market, 2021 - 2033 (USD Billion)
- 5.7. Malaria Chemoprophylaxis
- 5.7.1. Malaria Chemoprophylaxis Market, 2021 - 2033 (USD Billion)
Chapter 6. Malaria Therapeutics Market: Route of Administration Business Analysis
- 6.1. Route of Administration Market Share, 2025 & 2033
- 6.2. Route of Administration Segment Dashboard
- 6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2021 to 2033 (USD Billion)
- 6.4. Oral
- 6.4.1. Oral Market, 2021 - 2033 (USD Billion)
- 6.5. Parenteral
- 6.5.1. Parenteral Market, 2021 - 2033 (USD Billion)
Chapter 7. Malaria Therapeutics Market: Distribution Channel Business Analysis
- 7.1. Distribution Channel Market Share, 2025 & 2033
- 7.2. Distribution Channel Segment Dashboard
- 7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Billion)
- 7.4. Hospital Pharmacies
- 7.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Billion)
- 7.5. Retail Pharmacies
- 7.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Billion)
- 7.6. Online Pharmacies
- 7.6.1. Online Pharmacies Market, 2021 - 2033 (USD Billion)
- 7.7. Government & Institutional Procurement
- 7.7.1. Government & Institutional Procurement Market, 2021 - 2033 (USD Billion)
Chapter 8. Malaria Therapeutics Market: Regional Estimates & Trend Analysis
- 8.1. Regional Market Share Analysis, 2025 & 2033
- 8.2. Regional Market Dashboard
- 8.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
- 8.4. North America
- 8.4.1. North America Malaria Therapeutics Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Billion)
- 8.4.2. U.S.
- 8.4.2.1. Key Country Dynamics
- 8.4.2.2. Target Disease Prevalence
- 8.4.2.3. Regulatory Framework
- 8.4.2.4. Reimbursement Framework
- 8.4.2.5. U.S. Malaria Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.4.3. Canada
- 8.4.3.1. Key Country Dynamics
- 8.4.3.2. Target Disease Prevalence
- 8.4.3.3. Regulatory Framework
- 8.4.3.4. Reimbursement Framework
- 8.4.3.5. Canada Malaria Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.4.4. Mexico
- 8.4.4.1. Key Country Dynamics
- 8.4.4.2. Target Disease Prevalence
- 8.4.4.3. Regulatory Framework
- 8.4.4.4. Reimbursement Framework
- 8.4.4.5. Mexico Malaria Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.5. Europe
- 8.5.1. Europe Malaria Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.5.2. UK
- 8.5.2.1. Key Country Dynamics
- 8.5.2.2. Target Disease Prevalence
- 8.5.2.3. Regulatory Framework
- 8.5.2.4. Reimbursement Framework
- 8.5.2.5. UK Malaria Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.5.3. Germany
- 8.5.3.1. Key Country Dynamics
- 8.5.3.2. Target Disease Prevalence
- 8.5.3.3. Regulatory Framework
- 8.5.3.4. Reimbursement Framework
- 8.5.3.5. Germany Malaria Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.5.4. France
- 8.5.4.1. Key Country Dynamics
- 8.5.4.2. Target Disease Prevalence
- 8.5.4.3. Regulatory Framework
- 8.5.4.4. Reimbursement Framework
- 8.5.4.5. France Malaria Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.5.5. Italy
- 8.5.5.1. Key Country Dynamics
- 8.5.5.2. Target Disease Prevalence
- 8.5.5.3. Regulatory Framework
- 8.5.5.4. Reimbursement Framework
- 8.5.5.5. Italy Malaria Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.5.6. Spain
- 8.5.6.1. Key Country Dynamics
- 8.5.6.2. Target Disease Prevalence
- 8.5.6.3. Regulatory Framework
- 8.5.6.4. Reimbursement Framework
- 8.5.6.5. Spain Malaria Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.5.7. Denmark
- 8.5.7.1. Key Country Dynamics
- 8.5.7.2. Target Disease Prevalence
- 8.5.7.3. Regulatory Framework
- 8.5.7.4. Reimbursement Framework
- 8.5.7.5. Denmark Malaria Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.5.8. Sweden
- 8.5.8.1. Key Country Dynamics
- 8.5.8.2. Target Disease Prevalence
- 8.5.8.3. Regulatory Framework
- 8.5.8.4. Reimbursement Framework
- 8.5.8.5. Sweden Malaria Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.5.9. Norway
- 8.5.9.1. Key Country Dynamics
- 8.5.9.2. Target Disease Prevalence
- 8.5.9.3. Regulatory Framework
- 8.5.9.4. Reimbursement Framework
- 8.5.9.5. Norway Malaria Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.6. Asia Pacific
- 8.6.1. Asia Pacific Malaria Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.6.2. Japan
- 8.6.2.1. Key Country Dynamics
- 8.6.2.2. Target Disease Prevalence
- 8.6.2.3. Regulatory Framework
- 8.6.2.4. Reimbursement Framework
- 8.6.2.5. Japan Malaria Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.6.3. China
- 8.6.3.1. Key Country Dynamics
- 8.6.3.2. Target Disease Prevalence
- 8.6.3.3. Regulatory Framework
- 8.6.3.4. Reimbursement Framework
- 8.6.3.5. China Malaria Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.6.4. India
- 8.6.4.1. Key Country Dynamics
- 8.6.4.2. Target Disease Prevalence
- 8.6.4.3. Regulatory Framework
- 8.6.4.4. Reimbursement Framework
- 8.6.4.5. India Malaria Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.6.5. Australia
- 8.6.5.1. Key Country Dynamics
- 8.6.5.2. Target Disease Prevalence
- 8.6.5.3. Regulatory Framework
- 8.6.5.4. Reimbursement Framework
- 8.6.5.5. Australia Malaria Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.6.6. South Korea
- 8.6.6.1. Key Country Dynamics
- 8.6.6.2. Target Disease Prevalence
- 8.6.6.3. Regulatory Framework
- 8.6.6.4. Reimbursement Framework
- 8.6.6.5. South Korea Malaria Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.6.7. Thailand
- 8.6.7.1. Key Country Dynamics
- 8.6.7.2. Target Disease Prevalence
- 8.6.7.3. Regulatory Framework
- 8.6.7.4. Reimbursement Framework
- 8.6.7.5. Thailand Malaria Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.7. Latin America
- 8.7.1. Latin America Malaria Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.7.2. Brazil
- 8.7.2.1. Key Country Dynamics
- 8.7.2.2. Target Disease Prevalence
- 8.7.2.3. Regulatory Framework
- 8.7.2.4. Reimbursement Framework
- 8.7.2.5. Brazil Malaria Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.7.3. Argentina
- 8.7.3.1. Key Country Dynamics
- 8.7.3.2. Target Disease Prevalence
- 8.7.3.3. Regulatory Framework
- 8.7.3.4. Reimbursement Framework
- 8.7.3.5. Argentina Malaria Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.8. Middle East and Africa
- 8.8.1. Middle East and Africa Malaria Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.8.2. South Africa
- 8.8.2.1. Key Country Dynamics
- 8.8.2.2. Target Disease Prevalence
- 8.8.2.3. Regulatory Framework
- 8.8.2.4. Reimbursement Framework
- 8.8.2.5. South Africa Malaria Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.8.3. Saudi Arabia
- 8.8.3.1. Key Country Dynamics
- 8.8.3.2. Target Disease Prevalence
- 8.8.3.3. Regulatory Framework
- 8.8.3.4. Reimbursement Framework
- 8.8.3.5. Saudi Arabia Malaria Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.8.4. UAE
- 8.8.4.1. Key Country Dynamics
- 8.8.4.2. Target Disease Prevalence
- 8.8.4.3. Regulatory Framework
- 8.8.4.4. Reimbursement Framework
- 8.8.4.5. UAE Malaria Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.8.5. Kuwait
- 8.8.5.1. Key Country Dynamics
- 8.8.5.2. Target Disease Prevalence
- 8.8.5.3. Regulatory Framework
- 8.8.5.4. Reimbursement Framework
- 8.8.5.5. Kuwait Malaria Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Chapter 9. Competitive Landscape
- 9.1. Participant Overview
- 9.2. Company Market Position Analysis
- 9.3. Company Categorization
- 9.4. Strategy Mapping
- 9.5. Company Profiles/Listing
- 9.5.1. Novartis AG
- 9.5.1.1. Overview
- 9.5.1.2. Financial Performance
- 9.5.1.3. Product Benchmarking
- 9.5.1.4. Strategic Initiatives
- 9.5.2. GSK plc
- 9.5.2.1. Overview
- 9.5.2.2. Financial Performance
- 9.5.2.3. Product Benchmarking
- 9.5.2.4. Strategic Initiatives
- 9.5.3. Sanofi
- 9.5.3.1. Overview
- 9.5.3.2. Financial Performance
- 9.5.3.3. Product Benchmarking
- 9.5.3.4. Strategic Initiatives
- 9.5.4. Cipla Limited
- 9.5.4.1. Overview
- 9.5.4.2. Financial Performance
- 9.5.4.3. Product Benchmarking
- 9.5.4.4. Strategic Initiatives
- 9.5.5. Ipca Laboratories Limited
- 9.5.5.1. Overview
- 9.5.5.2. Financial Performance
- 9.5.5.3. Product Benchmarking
- 9.5.5.4. Strategic Initiatives
- 9.5.6. Sun Pharmaceutical Industries Limited
- 9.5.6.1. Overview
- 9.5.6.2. Financial Performance
- 9.5.6.3. Product Benchmarking
- 9.5.6.4. Strategic Initiatives
- 9.5.7. Ajanta Pharma Limited
- 9.5.7.1. Overview
- 9.5.7.2. Financial Performance
- 9.5.7.3. Product Benchmarking
- 9.5.7.4. Strategic Initiatives
- 9.5.8. Strides Pharma Science Limited
- 9.5.8.1. Overview
- 9.5.8.2. Financial Performance
- 9.5.8.3. Product Benchmarking
- 9.5.8.4. Strategic Initiatives
- 9.5.9. Shin Poong Pharmaceutical Co., Ltd.
- 9.5.9.1. Overview
- 9.5.9.2. Financial Performance
- 9.5.9.3. Product Benchmarking
- 9.5.9.4. Strategic Initiatives
- 9.5.10. KPC Pharmaceuticals, Inc.
- 9.5.10.1. Overview
- 9.5.10.2. Financial Performance
- 9.5.10.3. Product Benchmarking
- 9.5.10.4. Strategic Initiatives
- 9.5.1. Novartis AG
